Improved Renal Function in Initial Treatment Improves Patient Survival, Renal Outcomes, and Glucocorticoid-Related Complications in IgG4-Related Kidney Disease in Japan
© 2023 International Society of Nephrology. Published by Elsevier Inc..
Introduction: We aimed to clarify long-term renal prognosis, complications of malignancy, glucocorticoid (GC) toxicity, and mortality in immunoglobulin G4 (IgG4)-related kidney disease (IgG4-RKD).
Methods: Reviewing the medical records of 95 patients with IgG4-RKD, we investigated clinical and pathologic features at baseline, the course of renal function, complications of malignancy, GC toxicity, and mortality during follow-up (median 71 months). The standardized incidence ratio (SIR) of malignancy and standardized mortality ratio were calculated using national statistics. Factors related to outcomes were assessed by Cox regression analyses.
Results: At diagnosis, the median estimated glomerular infiltration rate (eGFR) was 46 ml/min per 1.73 m2. GC achieved initial improvement. Additional renal function recovery within 3-months of initial treatment occurred in patients with highly elevated serum IgG and IgG4 levels and hypocomplementemia. During follow-up, 68%, 17%, and 3% of the patients had chronic kidney disease (CKD), >30% eGFR decline, and end-stage renal disease (ESRD), respectively. Age-adjusted and sex-adjusted Cox regression analyses indicated that eGFR (hazard ratio [HR], 0.71) and extensive fibrosis (HR, 2.58) at treatment initiation had a significant impact on the time to CKD. Ten patients died, and the standardized mortality ratio was 0.94. The SIR of malignancy was 1.52. The incidence rate (IR) of severe infection was 1.80/100 person-years. Cox regression analyses showed that the best eGFR within 3 months after treatment initiation were associated with lower mortality (HR 0.67) and fewer severe infections (HR 0.63).
Conclusion: This study suggests that more renal function recovery through early treatment initiation may improve patient survival, renal outcomes, and some GC-related complications in IgG4-RKD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Kidney international reports - 9(2024), 1 vom: 31. Jan., Seite 52-63 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mizushima, Ichiro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Death |
|---|
| Anmerkungen: |
Date Revised 06.02.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.ekir.2023.10.016 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368019950 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368019950 | ||
| 003 | DE-627 | ||
| 005 | 20240206232215.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240205s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ekir.2023.10.016 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1282.xml |
| 035 | |a (DE-627)NLM368019950 | ||
| 035 | |a (NLM)38312790 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mizushima, Ichiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Improved Renal Function in Initial Treatment Improves Patient Survival, Renal Outcomes, and Glucocorticoid-Related Complications in IgG4-Related Kidney Disease in Japan |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 06.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 International Society of Nephrology. Published by Elsevier Inc. | ||
| 520 | |a Introduction: We aimed to clarify long-term renal prognosis, complications of malignancy, glucocorticoid (GC) toxicity, and mortality in immunoglobulin G4 (IgG4)-related kidney disease (IgG4-RKD) | ||
| 520 | |a Methods: Reviewing the medical records of 95 patients with IgG4-RKD, we investigated clinical and pathologic features at baseline, the course of renal function, complications of malignancy, GC toxicity, and mortality during follow-up (median 71 months). The standardized incidence ratio (SIR) of malignancy and standardized mortality ratio were calculated using national statistics. Factors related to outcomes were assessed by Cox regression analyses | ||
| 520 | |a Results: At diagnosis, the median estimated glomerular infiltration rate (eGFR) was 46 ml/min per 1.73 m2. GC achieved initial improvement. Additional renal function recovery within 3-months of initial treatment occurred in patients with highly elevated serum IgG and IgG4 levels and hypocomplementemia. During follow-up, 68%, 17%, and 3% of the patients had chronic kidney disease (CKD), >30% eGFR decline, and end-stage renal disease (ESRD), respectively. Age-adjusted and sex-adjusted Cox regression analyses indicated that eGFR (hazard ratio [HR], 0.71) and extensive fibrosis (HR, 2.58) at treatment initiation had a significant impact on the time to CKD. Ten patients died, and the standardized mortality ratio was 0.94. The SIR of malignancy was 1.52. The incidence rate (IR) of severe infection was 1.80/100 person-years. Cox regression analyses showed that the best eGFR within 3 months after treatment initiation were associated with lower mortality (HR 0.67) and fewer severe infections (HR 0.63) | ||
| 520 | |a Conclusion: This study suggests that more renal function recovery through early treatment initiation may improve patient survival, renal outcomes, and some GC-related complications in IgG4-RKD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a IgG4-related kidney disease | |
| 650 | 4 | |a death | |
| 650 | 4 | |a glucocorticoid | |
| 650 | 4 | |a malignancy | |
| 650 | 4 | |a outcome | |
| 650 | 4 | |a treatment | |
| 700 | 1 | |a Saeki, Takako |e verfasserin |4 aut | |
| 700 | 1 | |a Kobayashi, Daisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Sawa, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashi, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Taniguchi, Yoshinori |e verfasserin |4 aut | |
| 700 | 1 | |a Nakata, Hirosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Yamada, Kazunori |e verfasserin |4 aut | |
| 700 | 1 | |a Matsui, Shoko |e verfasserin |4 aut | |
| 700 | 1 | |a Yasuno, Tetsuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Masutani, Kosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Nagasawa, Tasuku |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Ubara, Yoshifumi |e verfasserin |4 aut | |
| 700 | 1 | |a Yanagita, Motoko |e verfasserin |4 aut | |
| 700 | 1 | |a Kawano, Mitsuhiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Kidney international reports |d 2016 |g 9(2024), 1 vom: 31. Jan., Seite 52-63 |w (DE-627)NLM264185072 |x 2468-0249 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2024 |g number:1 |g day:31 |g month:01 |g pages:52-63 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ekir.2023.10.016 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2024 |e 1 |b 31 |c 01 |h 52-63 | ||